International Journal of Medical and All Body Health Research  |  e-ISSN: 2582-8940  |  Double-Blind Peer Review  |  Open Access  |  CC BY-NC-SA 4.0

Current Issues
     2026:7/4

International Journal of Medical and All Body Health Research

e-ISSN: 2582-8940 | Open Access

King Salman Specialist Hospital study for use of hydroxychloroquine in COVID 19 positive patients at Hail region, and relation with cardiovascular risk factors

Vlachopoulou M, Chatzis G, Sulami A, Karish MA, Gawish AE, A Almofadhli AE, Alharbi AS, Alsairra MNS, Aljarbaa NK, Al Harbi MN, Almansori AND, Alnawmasi MON, Aldogeman RZM

Hail Cardiac Center, Hail, Saudi Arabia; Department of Internal Medicine, King Salman Specialist hospital, Hail, Saudi Arabia; University of Hail, Hail, Saudi Arabia

Article Information

Volume / Issue1 / 2 (April-June 2020)
Pages15-18
AccessOpen Access

Publication Timeline

  • Received14 April 2020
  • Accepted30 April 2020

Full Text (PDF)

Open Access - Free to Download

Download Full Article (PDF) JATS XML

Abstract

Introduction: Hydroxychloroquine (HCQ) is an antimalarial drug that received worldwide news and media attention in the treatment of patients with coronavirus disease 2019 (COVID19). This drug was used on the basis of its antimicrobial and antiviral properties despite lack of definite evidence of clinical efficacy. In this study, we aim to assess the efficacy and safety of using HCQ in treatment of patients with COVID-19 who were admitted in King Salman Specialist Hospital, at Hail, KSA. rnMethods: We conducted a retrospective cohort study on a random sample of patients admitted with COVID-19 between 1 April and 31 July 2020. The study was conducted in King Salman Specialist Hospital, Hail, KSA. Data was extracted from the medical records. The primary endpoint was the requirement of noninvasive ventilation, intubation, or death. Secondary endpoint was length of hospitalization for survivors and readmissions. Three methods of analysis were used to control for confounding factors: logistic multivariate regression, propensity score adjusted regression, and matched propensity score analysis. rnResults: A random sample of 753 patients were included, 348 of whom received HCQ (treatment group) and 405 did not receive it (control group). Our results showed that HCQ did have a significant effect on primary outcomes due to COVID-19 infection when compared to controls after adjusting (P = 0.011). Co-administration of aspirin and dexamethasone had also effect on primary outcomes (P = 0.011). Morbid Obesity was associated with increased risk of primary and secondary outcome (P = 0.005) rnHydroxochloroquine was not associated with QT prolongation or cardiac arrhythmia. rnConclusion: Our results showed some beneficial effect of using hydroxychloroquine on the outcome of patients with COVID-19, and also aspirin and dexamethasone. Obesity however, in combination with diabetes mellitus, is a significant cardiovascular risk in patients with COVID 19 infection

Keywords

ObesityAspirinCOVID-19EfficacyHydroxychloroquineRespiratory failureSafetySARS-CoV-2Cardiovascular disease

References

  1. World Health Organization. WHO coronavirus disease (COVID-19) dashboard. WHO , 2020. https://covid19.who.int.Acceses on 10/5/2021 [Google Scholar][Crossref]
  2. Principi N, Esposito S. Chloroquine or hydroxychloroquine for prophylaxis of COVID-19. Lancet Infect Dis 2020; published online April 17. https://doi.org/10.1016/S1473-3099(20)30296-6. [Google Scholar][Crossref]
  3. Perricone C, Triggianese P, Bartoloni E, et al. The anti-viral facet of anti-rheumatic drugs: lessons from COVID-19. J Autoimmun 2020. Published online April 17. DOI:10.1016/j.jaut.2020.102468. [Google Scholar][Crossref]
  4. Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020; 6:16. [Google Scholar][Crossref]
  5. Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents, 2020. Published online March 12. DOI:10.1016/j.ijantimicag.2020.105938. [Google Scholar][Crossref]
  6. Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients mainly with mild to moderate COVID-19: an open-label, randomized, controlled trial. Med Rxiv, 2020. Published online May 7. DOI:10.1101/2020.04.10.20060558 (preprint). [Google Scholar][Crossref]
  7. Chen J, Liu D, Liu L, et al. A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19. J Zhejiang Univ (Med Sci). 2020; 49:215-19. [Google Scholar][Crossref]
  8. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents, 2020. Published online March 20. DOI:10.1016/j.ijantimicag.2020.105949. [Google Scholar][Crossref]
  9. Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012; 366:1881-90. [Google Scholar][Crossref]
  10. Giudicessi JR, Noseworthy PA, Friedman PA, Ackerman MJ. Urgent guidance for navigating and circumventing the QTc-prolonging and torsadogenic potential of possible pharmacotherapies for coronavirus disease 19 (COVID-19). Mayo Clin Proc, 2020. Published online April 7. DOI:10.1016/j. mayocp.2020.03.024. [Google Scholar][Crossref]
  11. Covid-19 Infection and Anti-Aging Gene Inactivation. Acta Scientific Nutritional Health 4.5, 2020, 01-02. [Google Scholar][Crossref]
  12. Horby P, Mafham M, Linsell L, et al. Effect of hydroxychloroquine in hospitalized patients with covid-19. N Engl J Med. 2020; 1:2. [Google Scholar][Crossref]
  13. Axfors C, Schmitt AM, Janiaud P, Van't Hooft J, Abd-Elsalam S, Abdo EF, et al. Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Nat Commun. 2021; 12(1):2349. Doi: 10.1038/s41467-021-22446-z [Google Scholar][Crossref]

How to Cite

M, V., G, C., A, S., MA, K., AE, G., AE, A. A., AS, A., MNS, A., NK, A., MN, A. H., AND, A., MON, A., & RZM, A. (2020). King Salman Specialist Hospital study for use of hydroxychloroquine in COVID 19 positive patients at Hail region, and relation with cardiovascular risk factors. International Journal of Medical and All Body Health Research, 1(2), 15-18.

M, Vlachopoulou, et al. "King Salman Specialist Hospital study for use of hydroxychloroquine in COVID 19 positive patients at Hail region, and relation with cardiovascular risk factors." International Journal of Medical and All Body Health Research, vol. 1, no. 2, 2020, pp. 15-18.

M, V., G, C., A, S., MA, K., AE, G., AE, A. A., AS, A., MNS, A., NK, A., MN, A. H., AND, A., MON, A. and RZM, A. (2020) 'King Salman Specialist Hospital study for use of hydroxychloroquine in COVID 19 positive patients at Hail region, and relation with cardiovascular risk factors', International Journal of Medical and All Body Health Research, 1(2), pp. 15-18.

M V, G C, A S, MA K, AE G, AE AA, et al. King Salman Specialist Hospital study for use of hydroxychloroquine in COVID 19 positive patients at Hail region, and relation with cardiovascular risk factors. International Journal of Medical and All Body Health Research. 2020;1(2):15-18.

Similar Articles

Share

Find this Article on

Google Scholar Semantic Scholar OpenAlex ResearchGate BASE

A newly published article may take a few days to appear on these services.